1.	Dasatinib Combo With SMO Inhibitor (BMS-833923) Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA180-323, 2010-019480-11, NCT01218477
2.	Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923) Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA180-363, 2011-000083-10, NCT01357655
3.	A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA194-002, NCT00670189
4.	Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA194-003, NCT00884546
5.	A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA194-004, 2010-018743-33, NCT00909402
6.	A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA194-005, 2010-018745-56, NCT00927875
7.	Phase 1 Multiple Ascending Dose Study of BMS-833923 (XL139) in Subjects With Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA194-010, NCT01413906